OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Sobh on Ongoing Investigations of NSD2 in Modulating Immune Surveillance in Myeloma

May 12th 2025

Amin Sobh, PhD, discusses ongoing efforts to investigate the role of NSD2 expression in modulating immune surveillance in multiple myeloma.

Dr Bhat on the Limitations of Current Treatments for Double-Refractory CLL

May 12th 2025

Seema A. Bhat, MD, discusses the lack of highly effective treatment options for patients with double-refractory CLL.

Dr Garcia on the Effect of the Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan in in PSMA+ mCRPC

May 12th 2025

Jorge A. Garcia, MD, discusses the clinical impact of the FDA’s expanded approval of lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mCRPC.

Dr Murray on the Safety of Encorafenib/Binimetinib and Dabrafenib/Trametinib in BRAF V600E+ NSCLC

May 12th 2025

Joseph C. Murray, MD, PhD, discusses the safety profiles of encorafenib/binimetinib and dabrafenib/trametinib in patients with BRAF V600E–mutant NSCLC.

Dr Tarantino on Early-Stage HER2+ Breast Cancer Risk Stratification

May 12th 2025

Paolo Tarantino, MD, discusses the clinical implications of current risk stratification methods for patients with HER2-positive breast cancer.

Dr Jahan on the Role of T-DXd in HR+/HER2-Low Metastatic Breast Cancer

May 12th 2025

Nusrat Jahan, MD, explains the role of T-DXd as the first cytotoxic therapy in patients with HR-positive/HER2-low or -ultralow breast cancer.

Dr Graham on the Significance of the FDA Approval of Mirvetuximab Soravtansine in Ovarian Cancer

May 12th 2025

Deena M. Atieh Graham, MD, discusses the FDA approval of mirvetuximab soravtansine.

Dr Graham on Notable Ongoing Studies in Ovarian Cancer

May 9th 2025

Deena M. Atieh Graham, MD, discusses ongoing studies of note in patients with ovarian cancer following World Ovarian Cancer Day.

Dr Wagar on the Use of T-DXd in Patients With HER2+ Endometrial Cancer

May 9th 2025

Matthew Wagar, MD, discusses the addition of T-DXd to the HER2-positive endometrial cancer treatment paradigm.

Dr Fenske on Assessing the Role of Auto-HCT in the Current MCL Treatment Paradigm

May 9th 2025

Timothy S. Fenske, MD, MS, discusses the rationale for evaluating the role of standard auto-HCT in MCL given recent updates to the MCL treatment paradigm.

Dr Uboha on the Role of Biomarkers for Guiding Esophageal Adenocarcinoma Treatment Selection

May 8th 2025

Nataliya Uboha, MD, PhD, discusses how biomarkers help guide treatment decision-making in esophageal adenocarcinoma.

Dr Lopetegui-Lia on Ongoing ADC Research in Metastatic TNBC

May 8th 2025

Nerea Lopetegui-Lia, MD, elaborates on several highly anticipated studies evaluating ADCs that could shape the future TNBC treatment paradigm.

Dr Zeidan on the Evaluation of Immunotherapy and Other Novel Therapies in MDS

May 8th 2025

Amer Zeidan, MBBS, discusses completed and ongoing research evaluating immunotherapy and other novel agents in patients with myelodysplastic syndromes.

Dr Komrokji on the Expanded Indication for Luspatercept in Lower-Risk MDS

May 8th 2025

Rami Komrokji, MD, discusses several trials that supported the FDA approval of luspatercept for the treatment of patients with MDS with anemia.

Dr Monk on the FDA Approval of Avutometinib and Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8th 2025

Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

Dr Kahl on the Outcomes of Bortezomib Plus BR in MCL

May 8th 2025

Brad S. Kahl, MD, details the outcomes of bortezomib plus bendamustine/rituximab in patients with mantle cell lymphoma.

Dr Pimenta on Novel Approaches to Evaluate Tumor Progression and Immune Evasion in Soft Tissue Sarcomas

May 7th 2025

Erica Maria Pimenta, MD, PhD, discusses the future for evaluating tumor progression and immune evasion in soft tissue sarcomas.

Dr Kruse on Long-Term Data for Adjuvant Abemaciclib Plus Endocrine Therapy in HR+/ HER2– Early Breast Cancer

May 7th 2025

Megan Kruse, MD, discusses long-term outcomes adjuvant abemaciclib with endocrine therapy in HR-positive, HER2-negative, high-risk early breast cancer.

Dr Mar on Challenges With ARPI Rechallenge in Prostate Cancer

May 7th 2025

Nataliya Mar, MD, discusses attempts to develop mechanisms for resensitizing prostate tumors to ARPI rechallenge.

Dr Grivas on Incorporating Perioperative Durvalumab Plus Neoadjuvant Chemo into MIBC Management

May 7th 2025

Petros Grivas, MD, PhD, details questions and considerations for integrating perioperative durvalumab plus neoadjuvant chemotherapy into MIBC management.